Interrelationship between protein phosphatase-2A and cytoskeletal architecture during the endothelial cell response to soluble products produced by human head and neck cancer.
Tumor neovascularization is necessary for the progressive development of all solid tumors, including head and neck squamous cell carcinomas (HNSCCs). The angiogenic process includes increased endothelial cell motility. Our prior studies have shown the importance of protein phosphatase-2A (PP-2A) in restricting endothelial cell motility. Because motility is regulated by the polymerization/depolymerization of the cellular cytoskeleton, the present study defined the interrelationship between PP-2A and the cytoskeleton during endothelial cell responses to HNSCC-derived angiogenic factors. PP-2A was shown to colocalize with microtubules of unstimulated endothelial cells. However, exposure to HNSCC-derived products resulted in a more diffuse distribution of PP-2A staining and a loss of filamentous tubulin. The feasibility of pharmacologically preventing this cytoskeletal disorganization as a means of blocking tumor-induced angiogenesis was tested. This was accomplished by use of 1alpha,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] and all-trans -retinoic acid to indirectly stimulate PP-2A activity through their capacity to elevated intracellular levels of the second messenger ceramide. Pretreatment of endothelial cells with either 1,25(OH)(2)D(3) or retinoic acid prevented the cytoskeletal disorganization that otherwise occurs in endothelial cells on exposure to HNSCC-derived products. These studies support the feasibility of using elevation of PP-2A to prevent the morphogenic component of the angiogenic process that is stimulated by HNSCC-derived factors.
Witt
C J
CJ
Department of Otolaryngology-Head and Neck Surgery, Loyola University Medical Center, Maywood, Illinois, USA.
Gabel
S P
SP
Meisinger
J
J
Werra
G
G
Liu
S W
SW
Young
M R
MR
D043925:Angiogenesis Inducing Agents / Q000378:metabolism / Q000494:pharmacology*; D015153:Blotting, Western; D002117:Calcitriol / Q000494:pharmacology; D002294:Carcinoma, Squamous Cell / Q000098:blood supply / Q000378:metabolism*; D002455:Cell Division; D002465:Cell Movement; D017077:Culture Media, Conditioned; D003599:Cytoskeleton / Q000648:ultrastructure*; D004730:Endothelium, Vascular / Q000503:physiopathology* / Q000648:ultrastructure; D004789:Enzyme Activation; D006258:Head and Neck Neoplasms / Q000098:blood supply / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D008870:Microtubules / Q000201:enzymology; D009389:Neovascularization, Pathologic / Q000503:physiopathology*; D010749:Phosphoprotein Phosphatases / Q000502:physiology*; D054648:Protein Phosphatase 2; D014212:Tretinoin / Q000494:pharmacology; D014404:Tubulin / Q000648:ultrastructure; D014407:Tumor Cells, Cultured / Q000502:physiology / Q000648:ultrastructure
D043925:Angiogenesis Inducing Agents; D017077:Culture Media, Conditioned; D014404:Tubulin; D014212:Tretinoin; D010749:Phosphoprotein Phosphatases; D054648:Protein Phosphatase 2; D002117:Calcitriol